Imprida HCT
amlodipine / valsartan / hydrochlorothiazide
Table of contents
Overview
The marketing authorisation for Imprida HCT has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Authorisation details
| Product details | |
|---|---|
| Name |
Imprida HCT
|
| Agency product number |
EMEA/H/C/001161
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
|
| Therapeutic area (MeSH) |
Hypertension
|
| Anatomical therapeutic chemical (ATC) code |
C09DX01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Novartis Europharm Ltd.
|
| Revision |
3
|
| Date of issue of marketing authorisation valid throughout the European Union |
15/10/2009
|
| Contact address |
Novartis Europharm Limited
Wimblehurst Road Horsham West Sussex, RH12 5AB United Kingdom |
Product information
20/10/2012 Imprida HCT - EMEA/H/C/001161 - WS/0250/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Angiotensin II antagonists, plain
-
Angiotensin II antagonists, combinations
Therapeutic indication
Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.